key: cord-0885433-jhhz05td
authors: Tang, Ning; Bai, Huan; Xiong, Dongsheng; Sun, Ziyong
title: Specific coagulation markers may provide more therapeutic targets in COVID‐19 patients receiving prophylactic anticoagulant
date: 2020-07-03
journal: J Thromb Haemost
DOI: 10.1111/jth.14988
sha: 10427e0b47d8b7be65b6a1ba4f185e6a7a39d2cd
doc_id: 885433
cord_uid: jhhz05td

I read with interest the recent published article from Professor Robert L. Medcalf, entitled “Fibrinolysis and COVID‐19: a plasmin paradox” [1]. As an indirect marker of thrombin and plasmin activation, D‐dimer has been suggested to guide anticoagulant treat in COVID‐19 patients [2, 3]. However, D‐dimer may not be able to reflect accurate fibrinolysis status of COVID‐19 patients, and therefore can’t guide the possible antifibrinolysis or thrombolytic therapy in different stages of COVID‐19, as Professor Robert L. Medcalf discussed. Hence, we speculated that measuring direct markers of thrombin, plasmin and so on, may provide more therapeutic targets in COVID‐19 patients with coagulopathy.

Dear Editor, I read with interest the recent published article from Professor Robert L. Medcalf, entitled "Fibrinolysis and COVID-19: a plasmin paradox" [1] . As an indirect marker of thrombin and plasmin activation, D-dimer has been suggested to guide anticoagulant treat in COVID-19 patients [2, 3] .

However, D-dimer may not be able to reflect accurate fibrinolysis status of COVID-19 patients, and therefore can't guide the possible antifibrinolysis or thrombolytic therapy in different stages of COVID-19, as Professor Robert L. Medcalf discussed. Hence, we speculated that measuring direct markers of thrombin, plasmin and so on, may provide more therapeutic targets in COVID-19 patients with coagulopathy.

For describing the intuitive coagulation and fibrinolysis feature of COVID-19 patients, we randomly enrolled 20 patients with critical COVID-19 and entering intensive care unit (ICU) of Tongji Hospital in Wuhan from February 1 to February 20, 2020, all of these patients stayed in ICU for 15-20 days and received prophylactic dose of low molecular weight heparin (LMWH) for at least 7 days.

Their residual plasma samples for routine coagulation tests during ICU stay were reserved at -70 degrees. Recently, we detected the levels of thrombin-antithrombin complex (TAT), plasmin-antiplasmin complex (PAP) and tissue plasminogen activator-plasminogen activator inhibitor 1 complex (tPAI-C) of these samples using a HISCL 5000 analyser and original chemiluminescence reagents (SYSMEX, Kobe, Japan), levels of these three markers reflect activities of thrombin, plasmin and plasminogen activator inhibitor-1 (PAI-1), respectively.

Eventually, 8 patients (40%) died and 12 patients discharged, the results of D-dimer, prothrombin time (PT), platelet count, TAT and PAP on day 1, 4, 7, 10 and 14 between survivors and Accepted Article non-survivors were compared, respectively (Figure 1 ). In addition, the results of tPAI-C on day 1 and 14 between survivors and non-survivors were also compared.

Perhaps due to that LMWH were routinely used in all of the enrolled patients, no significant difference on results of D-dimer, PT and platelet count during the early and middle stage were found between survivors and non-survivors. There were 3 (37.5%) of the non-survivors met the International Society on Thrombosis and Haemostasis (ISTH) diagnostic criteria for disseminated intravascular coagulation (DIC) during ICU stay, this incidence rate was also lower than that in our previous study (71.4%, P<0.05) [4] .

Interestingly, the other specific coagulation markers we detected might provide more therapeutic targets: the higher TAT levels in non-survivors than in survivors during the early and middle stage reflected more excess generation of thrombin [5] , and might indicate higher dose of anticoagulant; the higher tPAI-C levels in non-survivors than in survivors during the middle and late stage reflected fibrinolysis shutdown due to endothelial dysfunction [6] , and might indicate further thrombolytic therapy with tissue plasminogen activator.

Although D-dimer levels in non-survivors increased significantly at the late stage, the PAP levels in them were decreased and significantly lower than survivors, it perhaps implied a hypofibrinolysis status due to increased PAI-1 (reflected by tPAI-C level) as well as excess consumption of plasminogen [7] . Hence, PAP levels could reflect more accurate fibrinolytic status than D-dimer at the late stage, and avoid unnecessary (even harmful) anti-fibrinolytic therapy in critical COVID-19

patients. In addition, as Professor Robert L. Medcalf mentioned in his article, if an antifibrinolytic agent such as tranexamic acid was to be given early to COVID-19 patients for inhibiting infectivity of coronavirus, at what point would this need to be stopped? We consider that PAP level may be used to guide the antifibrinolysis therapy with appropriate thresholds.

Our study was retrospective and with small sample size, the results should be confirmed in an adequately powered intervention study. As the mortality seems still high in critical COVID-19 patients receiving prophylactic anticoagulant, whether treatment strategies based on these specific coagulation markers could further improve outcome of critical COVID-19 patients was the issue worthy of investigation.

Fibrinolysis and COVID-19: a plasmin paradox

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation

Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study

This article is protected by copyright. All rights reserved 

The authors declare that they have no conflicts of interest.